[1] |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
|
[2] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
|
[3] |
TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
|
[4] |
SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. DOI: 10.1016/S0140-6736(18)31865-8.
|
[5] |
WANG X, LIU X, DANG Z, et al. Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis[J]. Gut Liver, 2020, 14(2): 232-247. DOI: 10.5009/gnl18546.
|
[6] |
CHOI WM, YIP TC, LIM YS, et al. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments[J]. J Hepatol, 2022, 76(1): 186-194. DOI: 10.1016/j.jhep.2021.09.017.
|
[7] |
LIAW YF, SUNG JJ, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364.
|
[8] |
HOSAKA T, SUZUKI F, KOBAYASHI M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J]. Hepatology, 2013, 58(1): 98-107. DOI: 10.1002/hep.26180.
|
[9] |
BONILLA GUERRERO R, ROBERTS LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma[J]. J Hepatol, 2005, 42(5): 760-777. DOI: 10.1016/j.jhep.2005.02.005.
|
[10] |
PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
|
[11] |
KIM WR, LOOMBA R, BERG T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Cancer, 2015, 121(20): 3631-3638. DOI: 10.1002/cncr.29537.
|
[12] |
CHOI J, KIM HJ, LEE J, et al. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: A Korean Nationwide Cohort Study[J]. JAMA Oncol, 2019, 5(1): 30-36. DOI: 10.1001/jamaoncol.2018.4070.
|
[13] |
ZHANG H, ZENG W. Lower risk of hepatocellular carcinoma with Tenofovir vs Entecavir in patients with chronic hepatitis B[J]. JAMA Oncol, 2019, 5(6): 914-915. DOI: 10.1001/jamaoncol.2019.0641.
|
[14] |
CHOI J, KO MJ, LIM YS. Lower risk of hepatocellular carcinoma with Tenofovir vs Entecavir in patients with chronic hepatitis B-in reply[J]. JAMA Oncol, 2019, 5(6): 916-917. DOI: 10.1001/jamaoncol.2019.0650.
|
[15] |
KIM SU, SEO YS, LEE HA, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea[J]. J Hepatol, 2019, 71(3): 456-464. DOI: 10.1016/j.jhep.2019.03.028.
|
[16] |
LEE SW, KWON JH, LEE HL, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis[J]. Gut, 2020, 69(7): 1301-1308. DOI: 10.1136/gutjnl-2019-318947.
|
[17] |
PAPATHEODORIDIS GV, DALEKOS GN, IDILMAN R, et al. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B[J]. J Hepatol, 2020, 73(5): 1037-1045. DOI: 10.1016/j.jhep.2020.06.011.
|
[18] |
TSENG CH, HSU YC, CHEN TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(12): 1039-1052. DOI: 10.1016/S2468-1253(20)30249-1.
|
[19] |
CHOI WM, CHOI J, LIM YS. Effects of Tenofovir vs Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 246-258. e9. DOI: 10.1016/j.cgh.2020.05.008.
|
[20] |
DAVE S, PARK S, MURAD MH, et al. Comparative effectiveness of Entecavir versus Tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. Hepatology, 2021, 73(1): 68-78. DOI: 10.1002/hep.31267.
|
[21] |
GU L, YAO Q, SHEN Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2020, 35(9): 1467-1476. DOI: 10.1111/jgh.15036.
|
[22] |
LI M, LV T, WU S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: A critical systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(1): 105-114. DOI: 10.1007/s12072-019-10005-0.
|
[23] |
YIP TC, WONG VW, CHAN HL, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than Entecavir in patients with chronic HBV infection in China[J]. Gastroenterology, 2020, 158(1): 215-225. e6. DOI: 10.1053/j.gastro.2019.09.025.
|
[24] |
LIU H, SHI Y, HAYDEN JC, et al. Tenofovir treatment has lower risk of hepatocellular carcinoma than Entecavir treatment in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. Liver Cancer, 2020, 9(4): 468-476. DOI: 10.1159/000507253.
|
[25] |
ZHANG Z, ZHOU Y, YANG J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: A meta analysis[J]. BMC Cancer, 2019, 19(1): 511. DOI: 10.1186/s12885-019-5735-9.
|
[26] |
VIGANÒ M, LOGLIO A, GROSSI G, et al. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?[J]. Expert Rev Anti Infect Ther, 2018, 16(2): 153-161. DOI: 10.1080/14787210.2018.1428561.
|
[27] |
CHAN HLY, LIM YS, SETO WK. Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)[J]. Gut, 2020, 69(Suppl 2): A1-A95. DOI: org/ 10.1136/gutjnl-2020-IDDF.144.
|
[28] |
LEE HW, CHO YY, LEE H, et al. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B[J]. J Viral Hepat, 2021, 28(11): 1570-1578. DOI: 10.1111/jvh.13601.
|
[29] |
YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70(3): 361-370. DOI: 10.1016/j.jhep.2018.10.014.
|
[30] |
CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
|
[31] |
REN H, HUANG Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(Suppl 1): 5-31. DOI: 10.1111/jvh.13150.
|
[32] |
Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
|
[33] |
BRUNETTO MR, BONINO F. Interferon therapy of chronic hepatitis B[J]. Intervirology, 2014, 57(3-4): 163-170. DOI: 10.1159/000360941.
|
[34] |
LEE SK, KWON JH, LEE SW, et al. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B[J]. Liver Int, 2021, 41(2): 288-294. DOI: 10.1111/liv.14701.
|
[35] |
REN P, CAO Z, MO R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk[J]. Expert Opin Biol Ther, 2018, 18(10): 1085-1094. DOI: 10.1080/14712598.2018.1518423.
|
[36] |
YANG S, LIN Q, LIN W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: A systematic review[J]. World J Surg Oncol, 2016, 14(1): 159. DOI: 10.1186/s12957-016-0912-7.
|
[37] |
LIANG KH, HSU CW, CHANG ML, et al. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B[J]. J Infect Dis, 2016, 213(6): 966-974. DOI: 10.1093/infdis/jiv547.
|
[38] |
MAO QG, LIANG HQ, YIN YL, et al. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B[J]. Clin Res Hepatol Gastroenterol, 2021, 46(1): 101758. DOI: 10.1016/j.clinre.2021.101758.
|
[39] |
LI SY, LI H, XIONG YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24(Suppl 1): 12-20. DOI: 10.1111/jvh.12755.
|